---
document_datetime: 2026-01-09 11:23:35
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ayvakyt-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ayvakyt-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1867076
conversion_datetime: 2026-01-10 11:03:44.762065
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## AYVAKYT

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.I.b.1 Change in the specification | 18/12/2025                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000314420                     | parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000275571 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with CYP3A substrates based on the final results from study BLU-285-1107 listed as a category 3 study in the RMP. This is a drug-drug interaction study to investigate the effect of 300 mg once daily avapritinib on the pharmacokinetics (PK) of midazolam in patients with unresectable or metastatic Gastrointestinal Stromal Tumors (GIST) and other Advanced Solid Tumors. The MAH also updated PBPK model to extend the clinical findings of Study BLU-285-1107 and simulate the effects of lower doses of avapritinib on the pharmacokinetics of midazolam and its metabolite. The package leaflet is updated accordingly. In addition, | 27/11/2025 | SmPC and PL | SmPC new text Section 4.5 Interaction with other medicinal products and other forms of interaction Co-administration of avapritinib 300 mg once daily with oral midazolam increased the midazolam AUC and Cmax by 51% and 20%, respectively. These results indicate that avapritinib 300 mg once daily is a weak inhibitor of CYP3A. Physiologically based pharmacokinetic simulations predict that avapritinib is not an inhibitor of CYP3A at doses of 200 mg once daily and below. Therefore, caution must be exercised with co-administration of avapritinib 300 mg once daily with narrow therapeutic index CYP3A substrates as their plasma concentrations may be increased |

<div style=\"page-break-after: always\"></div>

|                                          | list of local representatives in the Package Leaflet to bring the PI in line with the latest QRD template version 10.4. The RMP version 5.1 has also been approved.                                                                           |            |            |                                                                                                                                                                                                                                                                                                  |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000307782    | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted                                                                                              | 18/11/2025 | N/A        |                                                                                                                                                                                                                                                                                                  |
| Variation type IA_IN / EMA/VR/0000303240 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.b Primary packaging site - Accepted                                                                  | 06/10/2025 | N/A        |                                                                                                                                                                                                                                                                                                  |
| PASS / EMA/PASS/0000282408               | - - PASS amendment [107o]: BLU-285-1406: an observational study evaluating safety and efficacy of avapritinib in the first line treatment of patients with Platelet derived Growth Factor Alpha D842V mutated gastrointestinal stromal tumor. | 04/09/2025 | N/A        |                                                                                                                                                                                                                                                                                                  |
| Renewal - 1 year / EMA/R/0000257352      | - Renewal - Renewal of conditional marketing authorisation                                                                                                                                                                                    | 22/05/2025 | 28/07/2025 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently |

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     | demonstrated and therefore recommends the renewal of the conditional MA for AYVAKYT, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000256554 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted | 27/03/2025 | N/A |                                                                                                                                                                                    |
| Variation type II / EMA/VR/0000245081 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27/03/2025 | N/A |                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                       | Submission of the final report from study BLU-285-1101 (BLU-R7289R1). This is a bioanalytical study titled: LC-MS/MS Determination of BLU-285 (Avapritinib) and Metabolites in K2EDTA Human Plasma Samples Originating from Study BLU-285- 1101: \"A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractor Solid Tumors\".   |            |     |             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000246539 | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted                                                                                                                                                                                                                               | 24/02/2025 | N/A |             |
| PSUR / EMA/PSUR/0000268946            | - -                                                                                                                                                                                                                                                                                                                                                                                    |            |     | Maintenance |